key: cord-0295781-o39x43fv
authors: Planchais, Cyril; Fernández, Ignacio; Bruel, Timothée; Dias de Melo, Guilherme; Prot, Matthieu; Beretta, Maxime; Guardado-Calvo, Pablo; Dufloo, Jérémy; Molinos-Albert, Luis M.; Backovic, Marija; Chiaravalli, Jeanne; Giraud, Emilie; Vesin, Benjamin; Conquet, Laurine; Grzelak, Ludivine; Planas, Delphine; Staropoli, Isabelle; Guivel-Benhassine, Florence; Boullé, Mikaël; Cervantes-Gonzalez, Minerva; Ungeheuer, Marie-Noëlle; Charneau, Pierre; van der Werf, Sylvie; Agou, Fabrice; Dimitrov, Jordan D.; Simon-Lorière, Etienne; Bourhy, Hervé; Montagutelli, Xavier; Rey, Félix A.; Schwartz, Olivier; Mouquet, Hugo
title: Potent Human Broadly SARS-CoV-2 Neutralizing IgA and IgG Antibodies Effective Against Omicron BA.1 and BA.2
date: 2022-04-01
journal: bioRxiv
DOI: 10.1101/2022.04.01.486719
sha: f0c18947c1f7a97799fd21e779d05902e9711ff0
doc_id: 295781
cord_uid: o39x43fv

Memory B-cell and antibody responses to the SARS-CoV-2 spike protein contribute to long-term immune protection against severe COVID-19, which can also be prevented by antibody-based interventions. Here, wide SARS-CoV-2 immunoprofiling in COVID-19 convalescents combining serological, cellular and monoclonal antibody explorations, revealed humoral immunity coordination. Detailed characterization of a hundred SARS-CoV-2 spike memory B-cell monoclonal antibodies uncovered diversity in their repertoire and antiviral functions. The latter were influenced by the targeted spike region with strong Fc-dependent effectors to the S2 subunit and potent neutralizers to the receptor binding domain. Amongst those, Cv2.1169 and Cv2.3194 antibodies cross-neutralized SARS-CoV-2 variants of concern including Omicron BA.1 and BA.2. Cv2.1169, isolated from a mucosa-derived IgA memory B cell, demonstrated potency boost as IgA dimers and therapeutic efficacy as IgG antibodies in animal models. Structural data provided mechanistic clues to Cv2.1169 potency and breadth. Thus, potent broadly neutralizing IgA antibodies elicited in mucosal tissues can stem SARS-CoV-2 infection, and Cv2.1169 and Cv2.3194 are prime candidates for COVID-19 prevention and treatment.

The coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory 18 syndrome coronavirus 2 (SARS-CoV-2), and accounts to date for nearly 480 million infection 19 cases and 6 million deaths worldwide (WHO, 2022). SARS-CoV-2 infects host cells through 20 interactions of its surface envelope protein, or spike, with the cellular angiotensin-converting 21 enzyme 2 (ACE2) receptor (Hoffmann et al., 2020; Lan et al., 2020) . The SARS-CoV-2 spike 22 (S) is a homo-trimeric glycoprotein with each protomer composed of subunits S1 and S2 ( (Kelley, 2020) . Immunotherapies based on SARS-CoV-2 neutralizing 40 antibodies have been rapidly explored, and this led to the clinical use of several monoclonal 41 antibodies (mAbs) alone or in bi-therapies (Corti et al., 2021) . Highly potent human SARS-42

CoV-2 neutralizing mAbs isolated so far, including those tested or used in clinics, all target the 43 RBD and can prevent infection and/or protect animals from severe disease in preclinical 44 ACE2 (Lan et al., 2020) . Thus, the F486 residue likely acts as an anchor for Cv2.1169, 291 strengthening its interaction with the RBM allowing to tolerate the T478K mutation in the δ and 292 δ + variants. Four of the Cv2.1169-RBD contacting residues are mutated in BA.1 and BA.2 293 variants, including the substitution K417N already present in β and γ, and T478K in δ, as well 294 as two Omicron-specific mutations S477N and Q493R (Tables S5). Although all of them are 295 at the periphery of Cv2.1169 binding site (Figures 6A-6C) , their combination explains the 296 decreased binding and neutralization of SARS-CoV-2 BA.1 and BA.2 compared to the other 297 VOCs (Figure 5) . 298

As afore-mentioned, Cv2.1169 leans towards the RBD's occluded face, making the 299 epitope inaccessible on the 'down' conformation ( Figure 6E ), which implies that the antibody 300 binds only to the RBD in its 'up' conformation. This was confirmed by the 2.8Å cryo-EM 301 reconstruction of the SARS-CoV-2 S_6P protein trimer in complex with Cv2.1169 IgA Fab (See 302 Figure S10 for the cryo-EM processing strategy). The map showed that the spike is in the 303 open form with each protomer bound by a Cv2.1169 Fab (Figure 6F ). Considering that 304

Cv2.1169 blocked SARS-CoV-2 tri-S binding to soluble ACE2 receptor, and that its binding 305 site is only accessible in the up-RBD conformation, our data suggest that the antibody belongs 306 to the class 1 category (or Ia) (Barnes et al., 2020b) , with an epitope in the RBD-B group (Yuan 307 et al., 2021) . Accordingly, Cv2.1169 cross-competed for binding to spike and RBD proteins 308 with class 1 benchmarked SARS-CoV-2 neutralizers (CT-P59, COV2-2196, REGN10933, and 309 CB6), but also moderately with class 2 antibody LY-CoV555 ( Figure S6D) . antibodies (1 mg i.p., ~10 mg/kg) ( Figure 7D ). Lung weight to body weight (LW/BW) ratio, 338 intra-lung viral infectivity and RNA load were measured at 5 dpi. Both pulmonary viral infectivity 339 and RNA levels in hamsters treated with Cv2.1169 were significantly reduced compared to 340 control animals (2.44x10 3 vs 10x10 5 PFU/lung, p=0.0005 and 4.3x10 7 vs 3.4x10 8 copies/µg 341 RNA, p=0.013, respectively) ( Figure 7D) . We next compared the in vivo activity of Cv2.1169 342 IgG and IgA antibodies at a dose ~5 mg/kg in hamsters 4h post-infection. IgA-and IgG-treated 343 hamsters showed a reduction in LW/BW ratio compared to control animals (1.64 vs 1.4 for IgA 344 [p=0.03] and 1.32 for IgG [p=0.004]) ( Figure 7E ). As expected from the rapid disappearance 345 of circulating human IgA antibodies in treated animals (Figure S11E) , the intra-lung viral 346 infectivity and RNA loads were comparable between SARS-CoV-2 neutralizing IgA-treated and 347 control hamsters ( Figure 7D ). In contrast, the administration of Cv2.1169 IgG antibodies 348 reduced both SARS-CoV-2 infectivity and RNA levels in the lungs of treated hamsters 349

(1.39x10 6 vs 80 PFU/lung, p=0.0002; 6.14x10 8 vs 1.51x10 8 copies/µg RNA, p=0.028) (Figure 350 (Figures S11B and S11C ). In addition, mice pre-treated with Cv2.1169 IgAs 366 developed higher anti-spike IgG antibody titers as compared to those treated with Cv2.1169 367 IgG antibodies, suggesting a weaker viral control in the former group ( Figure S11D) . serum IgA antibodies from COVID-19 convalescents neutralize SARS-CoV-2, often more 376 efficiently than their IgG counterparts despite their lower representativeness in the blood. IgA 377 neutralizing titers were correlated to anti-S1/-RBD antibody levels and spike + memory IgA B-378 cell frequencies, suggesting coordinated serological and cellular humoral responses in these 379 individuals as previously reported (Juno et al., 2020) . We also document an association 380 between spike-reactive resting memory IgG B cells and Th2-like cTfh cells, which likely 381 encompass spike-specific cTfh2 cells (Juno et al., 2020) . In this study, we characterized 382 SARS-CoV-2 spike-specific IgG + and IgA + memory B-cell antibodies from COVID-19 383 convalescent individuals with high seroneutralization titers. Surprisingly, only a minority (~7%) 384 of the antibodies -all targeting the RBD -efficiently neutralized SARS-CoV-2 in vitro. Other 385 less potent anti-RBD and several anti-NTD antibodies neutralizing SARS-CoV-2 were also 386 isolated as previously reported (Andreano et Besides neutralization, SARS-CoV-2 IgGs can exert antiviral effector functions 389 dependent or not on their binding to FcγR (i.e., ADCC/ADCP and CDC, respectively), playing 390 a role in the therapeutic protection against SARS-CoV-2 infection in vivo (Schäfer et al., 2021; 391 Winkler et al., 2021) . Here, we found that despite lacking high neutralization potential, anti-S2 392 and anti-NTD IgGs harbor strong Fc-dependent effector functions less frequently observed 393 with anti-RBD antibodies. This tendency suggests a dichotomy of antiviral functions based on 394 epitope specificity, with antibodies to the spike head (RBD) being neutralizers and those to the 395 stalk (S2) being effectors, while anti-NTD displayed mixed activities. Of note, one neutralizing 396 antibody termed S2P6 targeting the S2 stem helix peptide also mediates a strong ADCC 397 activity (Pinto et al., 2021) . 398

Among the 102 SARS-CoV-2 antibodies described in this study, Cv2.1169 and Cv2.3194 399 were the sole potent neutralizers with a sustained activity against all SARS-CoV-2 variants, 400 including Omicron BA.1 and BA.2 subtypes. Comparably to typical class 1 anti-RBD 401 antibodies, Cv2.3194 uses VH3-53 variable genes and displays a short CDRH3 (Yuan et al., 402 2020 (Yuan et al., 402 , 2021 , but differs from the others by its resistance to escape mutations in the VOCs. CoV-2 RBD, S1 subunit, S1 N-terminal domain (NTD), S1 connecting domain (CD), 498 nucleocapsid protein (N), BA.1 and BA.2 RBDs followed by C-terminal tags (Hisx8-tag, Strep-499 tag, and AviTag), as well as human angiotensin-converting enzyme 2 (ACE2) (plus Hisx8-and 500

Strep-tags), were cloned into pcDNA3. precipitation method as previously described (Lorin and Mouquet, 2015) . Proteins were 508 purified from culture supernatants by high-performance chromatography using the Ni 509

Sepharose® Excel Resin according to manufacturer's instructions (GE Healthcare), dialyzed 510 against PBS using Slide-A-Lyzer® dialysis cassettes (Thermo Fisher Scientific), quantified 511

using NanoDrop 2000 instrument (Thermo Fisher Scientific), and controlled for purity by SDS-512 PAGE using NuPAGE 3-8% Tris-acetate gels (Life Technologies), as previously described 513 (Lorin and Mouquet, 2015) . AviTagged tri-S and RBD proteins were biotinylated using BirA 514

biotin-protein ligase bulk reaction kit (Avidity, LLC) or Enzymatic Protein Biotinylation Kit 515 (Sigma-Aldrich). SARS-CoV-2 RDB protein was also coupled to DyLight 650 using the 516

DyLight® Amine-Reactive Dyes kit (Thermo Fisher scientific). 517

For crystallographic experiments, a codon-optimized nucleotide fragment encoding the 518 SARS-CoV-2 RBD protein (residues 331-528), followed by an enterokinase cleavage site and 519 a C-terminal double strep-tag was cloned into a modified pMT/BiP expression vector (pT350, 520

Invitrogen). Drosophila S2 cells were stably co-transfected with pT350 and pCoPuro (for 521

puromycin selection) plasmids. The cell line was selected and maintained in serum-free insect 522 cell medium (HyClone, Cytiva) supplemented with 7 µg/ml puromycin and 1% 523 penicillin/streptomycin antibiotics. Cells were grown to reach a density of 1  10 7 cells/ml, and 524

protein expression was then induced with 4 M CdCl 2 . After 6 days of culture, the supernatant 525 was collected, concentrated and proteins were purified by high-performance chromatography 526 using a Streptactin column (IBA). The eluate was buffer-exchanged into 10 mM Tris-HCl (pH 527 8.0), 100 mM NaCl, 2 mM CaCl2 using a HiPrep 26/10 Desalting column (GE Healthcare) and 528

subsequently treated with enterokinase overnight at room temperature to remove the strep-529

tag. Undigested tagged proteins were removed using a Streptactin column, and monomeric 530 untagged protein was purified by size-exclusion chromatography (SEC) using a Superdex 75 531 column (Cytiva) equilibrated with 10 mM Tris-HCl (pH 8.0), 100 mM NaCl. Purified monomeric 532 untagged protein was concentrated and stored at -80 C until used. 533

For Cryo-EM experiments, a codon-optimized nucleotide fragment encoding the SARS-534

CoV-2 spike (S) protein (residues 1-1208) was cloned with its endogenous signal peptide in 535

pcDNA3.1(+) vector, and expressed as a stabilized trimeric prefusion construct with six proline 536 substitutions (F817P, A892P, A899P, A942P, K986P, V987P), along with a GSAS substitution 537 at the furin cleavage site (residues 682-685), followed by a Foldon trimerization motif (Hsieh 538 et al., 2020), and C-terminal tags (Hisx8-tag, Strep-tag and AviTag). The recombinant protein, 539 S_6P, was produced by transient transfection of Expi293F TM cells (Thermo Fisher Scientific, 540

Waltham, MA) using FectroPRO  DNA transfection reagent (Polyplus), according to the 541 manufacturer's instructions. After 5 days of culture, recombinant proteins were purified from 542 the concentrated supernatant by affinity chromatography using a SrepTactin column (IBA), 543 followed by a SEC using a Superose 6 10/300 column (Cytiva) equilibrated in 10 mM Tris-HCl, 544 100 mM NaCl (pH 8.0). The peak corresponding to the trimeric protein was concentrated and 545 stored at -80 C until used. 546 547

Flow cytometry immunophenotyping 548

Peripheral blood mononuclear cells (PBMC) were isolated from donors' blood using Ficoll 549

Plaque Plus (GE Healthcare GenScript Biotech, 500 ng/well) was tested using the same procedure as previously described 641 (Wardemann, 2003) . For competition ELISAs, 250 ng/well of StrepTag-free tri-S and RBD 642 proteins were coated on ELISA plates (Costar, Corning), which were then blocked, washed, 643

and incubated for 2 h with biotinylated antibodies (at a concentration of 100 ng/ml for tri-S 644 competition and 25 ng/ml for RBD competition) in 1:2 serially diluted solutions of antibody 645 competitors in PBS (IgG concentration ranging from 0.39 to 50 µg/ml). Plates were developed 646 using HRP-conjugated streptavidin (BD Biosciences) as described above. For the competition 647 experiments of tri-S-and RBD-binding to ACE2, ELISA plates (Costar, Corning) were coated 648 overnight with 250 ng/well of purified ACE2 ectodomain. After washings, plates were blocked 649 2 h with Blocking buffer, PBST-washed, and incubated with recombinant IgG1 mAbs at 2 µg/ml 650 and 7 consecutive 1:2 dilutions in presence of biotinylated tri-S protein at 1 µg/ml in PBS, and 651

at 10 or 100 µg/ml and 7 consecutive 1:2 dilutions in PBS in presence of biotinylated RBD at 652 0.5 µg/ml. After washings, the plates were revealed by incubation for 30 min with streptavidin 653 HRP-conjugated (BD Biosciences) as described above. 654

Polyreactivity ELISA was performed as previously described ( tri-S and S1 proteins were serially diluted (two- IgA/IgG - value in "non-infected") / (value in "no IgA/IgG" - value in "non-infected")). IC50 values 760

were calculated using Prism software (v.9.3.1, GraphPad Prism Inc.) by fitting replicate values 761 using the four-parameters dose-response model (variable slope). 762 763

In vitro SARS-CoV-2 pseudoneutralization assay 764

The SARS-CoV-2 pseudoneutralization assay was performed as previously described ( µg of tri-S for 1 µl of beads), and incubated for 30 min at room temperature. After PBS 783 washings, tri-S coupled-beads 1:500-diluted in DMEM were incubated for 1 h at 37°C with 784 human IgG1 mAbs (at 3 µg/ml). tri-S-beads-antibody mixtures were then incubated with 7.5 x 785 10 4 human monocytes for 2 h at 37°C. Following washings with 0.5% BSA, 2 mM EDTA-PBS, 786 cells were fixed with 4% PFA-PBS and analyzed using a CytoFLEX flow cytometer (Beckman 787

Coulter). ADCP assays were performed in two independent experiments, and analyzed using 788 the FlowJo software (v10.6, FlowJo LLC). Phagocytic scores were calculated by dividing the 789 fluorescence signals (% FITC-positive cells x geometric MFI FITC-positive cells) given by anti-790 SARS-CoV-2 spike antibodies by the one of the negative control antibody mGO53. 791 792

Antibody-dependent cellular cytotoxicity (ADCC) assay 793

The ADCC activity of anti-SARS-CoV2 S IgG antibodies was determined using the ADCC 794

Reporter Bioassay (Promega) as previously described (Dufloo et al., 2021) . Briefly, 5x10 4 Raji-795

Spike cells were co-cultured with 5x10 4 Jurkat-CD16-NFAT-rLuc cells in presence or absence 796 of SARS-CoV2 S-specific or control mGO53 IgG antibody at 10 µg/ml or 50 µg/ml and 10 797 consecutive 1:2 dilutions in PBS. Luciferase was measured after 18 h of incubation using an 798

EnSpire plate reader (PerkinElmer). ADCC was measured as the fold induction of Luciferase 799 activity compared to the control antibody. Experiments were performed in duplicate in two 800 independent experiments. 801 802

Complement-dependent cytotoxicity (CDC) assay 803

The CDC activity of anti-SARS-CoV2 S IgG antibodies was measured using SARS-CoV-2 804

Spike-expressing Raji cells as previously described (Pelleau et al., 2020) . Briefly, 5x10 4 Raji-805

Spike cells were cultivated in the presence of 50% normal or heat-inactivated human serum, 806

and with or without IgG antibodies (at 10 µg/ml or 50 µg/ml and 10 consecutive 1:2 dilutions in 807 PBS cryosparc (Punjani et al., 2017) . CryoSPARC blob picker was used for automated particle 857

picking and the resulting particles used to obtain initial 2D references, which were then used 858

to auto-pick the micrographs. An initial 3D model was obtained in cryosparc and used to 859 perform a 3D classification without imposing any symmetry in Relion (Zivanov et al., 2018) . 860

The best class was selected and subjected to 3D, non-uniform refinement in cryosparc 861 (Punjani et al., 2020) . 1169 IgG or IgA antibody,  898 as well as the mGO53 control antibody or PBS. All hamsters were followed-up daily when the 899 body weight and the clinical score were noted. At day 5 post-inoculation, animals were 900 euthanized with an excess of anesthetics (ketamine and xylazine) and exsanguination (AVMA 901

Guidelines 2020). Blood samples were collected by cardiac puncture; after coagulation, tubes 902

were centrifuged at 1,500 x g during 10 min at 4°C, and sera were collected and frozen at -903 80°C until further analyses. The lungs were weighted and frozen at -80°C until further analyses. 904

Frozen lungs fragments were weighted and homogenized with 1 ml of ice-cold DMEM 905

(31966021, Gibco) supplemented with 1% penicillin/streptomycin (15140148, Thermo Fisher) 906

in (116913100, MP Biomedicals) using the FastPrep-24™ system (MP Biomedicals), and the 914 following scheme: homogenization at 6.5 m/s during 60 sec, and centrifugation at 12,000 x g 915 during 2 min at 4°C. The supernatants were collected and the total RNA was then extracted 916 using the Direct-zol RNA MiniPrep Kit (R2052, Zymo Research) and quantified using 917

NanoDrop 2000. The presence of genomic SARS-CoV-2 RNA in these samples was evaluated 918

by one-step RT-qPCR in a final volume of 25 μl per reaction in 96-well PCR plates using a 919 thermocycler (7500t Real-time PCR system, Applied Biosystems) as previously described 920 (Melo et al., 2021) . Viral load quantification (expressed as RNA copy number/µg of RNA) was 921 assessed by linear regression using a standard curve of six known quantities of RNA 922 transcripts containing the RdRp sequence (ranging from 10 7 to 10 2 copies). 923 924

Quantification and statistical analysis 925

The We are grateful to all participants who consented to be part of this study. We thank the 953 members of the Crystallography core facility (Institut Pasteur) for carrying out robot-driven 954 crystallization screeenings, and of the beamlines Proxima 1 and Proxima 2 at the French 955 national synchrotron facility (SOLEIL, St Aubin, France). We also thank the NanoImaging core 956 facility (Institut Pasteur) for support with sample preparation and image acquisition. The 957

NanoImaging Core was created with the help of a grant from the French Government's 958

Investissements d'Avenir program (EQUIPEX CACSICE, ANR-11-EQPX-0008). This work 959 was supported by grants from the ANR REACTing Covid19 (#20RR028-00), the European 960

Commission Horizon 2020 program (RECoVER project, #101003589), the Institut Pasteur 961

Task C   FC2  FC8  FC21  FC1  FC19  FC14  FC32  FC16  FC6  FC3  FC9  FC24  FC23  FC26  FC31  FC4  FC22  FC12  FC18  FC28  FC33  FC20  FC17  FC30  FC29  FC15  FC11  FC34  FC25  FC13  FC5  FC27  FC7  FC10 CoV2-S CoV2-RBD MERS-S 1 4 3 4 4 3 4 3 2 2 2 3 3 2 3 3 2 3 3 3 2 2 3 3 2 3 3 3 3 2 3 3 1 2 1 1 2 1 1 1 3 3 3 1 1 2 1 1 3 3 1 1 1 2 2 1 1 1 1 2 2 2 1 2 1 1 3 1 3 3 3 3 1 2 2 1 2 1 1 2 2 2 2 1 1 1 1 1 1 3 3 3 1 1 13 13 13 13 13 13 13 13 13 12 13 13 13 13 13 12 12 13 13 13 13 13 13 2 9 13 13 12 13 13 1 2 13 12 6 12 12 11 12 1 11 12 12 8 7 12 11 8 10 10 10 10 10 9 8 10 10 9 10 10 9 9 9 10 10 10 12 12 1 5 6 10 11 10 10 1 1 1 6 9 1 1 6 6 1 2 11 2 4 1 3 + Wuhan 

CoV-2 neutralizing antibodies with extended half-life could be used to provide protective 452 immunity in immunocompromised populations

References 984

Extremely potent human monoclonal antibodies from COVID-19 986 convalescent patients

High seroprevalence but short-lived immune response to SARS-CoV-2 989 infection in Paris

Viral concentration determination through plaque assays: Using 991 traditional and novel overlay systems

Structures of Human Antibodies

Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies

SARS-CoV-2 neutralizing antibody 998 structures inform therapeutic strategies

Sera Neutralizing Activities Against Severe Acute Respiratory 1001

Syndrome Coronavirus 2 and Multiple Variants 6 Months After Hospitalization for Coronavirus Disease

Potent neutralizing antibodies from COVID-19 1005 patients define multiple targets of vulnerability

Seroneutralization of Omicron BA.1 and BA.2 in patients receiving anti-1008 SARS-CoV-2 monoclonal antibodies

Syncytia formation by SARS-CoV-2-infected 1011 cells

Broadly neutralizing antibodies overcome SARS-CoV

Omicron antigenic shift

Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell 1017

Sequencing of Convalescent Patients' B Cells

Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies

2 specifically evades broad sarbecovirus neutralizing antibodies

Convergent antibody responses to the SARS-CoV-2 1025 spike protein in convalescent and vaccinated individuals

SARS-CoV-2 infection and persistence throughout the human body and brain 1028 National Institutes of Health

Tackling COVID-19 with neutralizing 1033 monoclonal antibodies

Antibody evasion by the P.1 strain of SARS-CoV-2

The antigenic anatomy of SARS-CoV-2 receptor binding 1039 domain

Genetic and structural basis for SARS-CoV-2 variant 1042 32 neutralization by a two-antibody cocktail

Asymptomatic and symptomatic SARS-CoV-2 infections elicit 1045 polyfunctional antibodies

Features and development of Coot

Evolution of antibody immunity to SARS-CoV-2

Deep Sequencing of B Cell Receptor

Repertoires From COVID-19 Patients Reveals Strong Convergent Immune Signatures

Broad and potent activity against SARS-1057 like viruses by an engineered human monoclonal antibody

COVID-19 prophylaxis in immunosuppressed patients: 1059 Beyond vaccination

Complete Mapping of Mutations to the SARS-CoV-2 Spike 1062 Receptor-Binding Domain that Escape Antibody Recognition

mRNA booster immunization elicits potent neutralizing serum activity against 1065 the SARS-CoV-2 Omicron variant

A comparison of four serological assays for detecting 1068 anti-SARS-CoV-2 antibodies in human serum samples from different populations

Molecular insights into receptor binding of recent emerging SARS-CoV-2 variants

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 1074 antibody cocktail

SARS-CoV-2 Cell Entry Depends on ACE2 and 1077 TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Structure-based design of prefusion-stabilized SARS-CoV-2 spikes

Syrian hamsters as a small animal model for SARS-CoV-2 1083 infection and countermeasure development

Asymptomatic and 1087 symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies

The neutralizing antibody, LY-CoV555, 1090 protects against SARS-CoV-2 infection in nonhuman primates

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Humoral and circulating follicular helper T cell responses in recovered 1095 patients with COVID-19

Structures and distributions of SARS-CoV-2 spike proteins on intact virions

Developing therapeutic monoclonal antibodies at pandemic pace

A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike 1103 protein

Engineering of recombinant crystallization chaperones

A correlate of protection for SARS-CoV-2 vaccines is urgently needed

Longitudinal Isolation of Potent Near-Germline SARS-1110

CoV-2-Neutralizing Antibodies from COVID-19 Patients

A Therapeutic Non-self-reactive SARS-CoV-2 Antibody 1113 Protects from Lung Pathology in a COVID-19 Hamster Model

Inference of Macromolecular Assemblies from Crystalline State

Current status of therapeutic monoclonal antibodies 1117 against SARS-CoV-2

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Macromolecular structure determination using X-rays, neutrons and 1123 electrons: Recent developments in Phenix

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

Human Circulating PD-1+CXCR3−CXCR5+ Memory Tfh Cells

Are Highly Functional and Correlate with Broadly Neutralizing HIV Antibody Responses

Antibody responses to SARS-CoV-2 in patients with COVID-19

Efficient generation of human IgA monoclonal antibodies

HIV-1 neutralizing IgA and IgG antibody lineages in a viremic controller

Surrogate Light Chain Expressing Human Peripheral B Cells Produce Self-reactive Antibodies

Attenuation of clinical and immunological outcomes during SARS-1143

CoV-2 infection by ivermectin

Attenuation of clinical and immunological outcomes during SARS-1146

CoV-2 infection by ivermectin

Human monoclonal antibody 1149 combination against SARS coronavirus: Synergy and coverage of escape mutants

Human Blood CXCR5+CD4+ T Cells Are 1153 Counterparts of T Follicular Cells and Contain Specific Subsets that Differentially Support Antibody 1154 Secretion

Memory B Cell Antibodies to HIV-1 gp140 Cloned from Individuals 1157 Infected with Clade A and B Viruses

Complex-type N-glycan 1160 recognition by potent broadly neutralizing HIV antibodies

Human B Cell Clonal Expansion and Convergent Antibody 1163 Responses to SARS-CoV-2

Therapeutic antibodies, targeting the SARS-CoV-2 spike N-1166 terminal domain, protect lethally infected K18-hACE2 mice

Asymptomatic and 1168 symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies

UCSF Chimera -A visualization system for exploratory research and analysis

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-1174

CoV antibody

Broad betacoronavirus neutralization by a stem helix-1177 specific human antibody

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and

1.351 variants to neutralizing antibodies

Reduced sensitivity of SARS-CoV-2 variant Delta to 1183 antibody neutralization

Considerable escape of SARS-CoV-2 Omicron to 1186 antibody neutralization

HIV-1 Envelope Recognition by Polyreactive and Cross-Reactive 1189 Intestinal B Cells

Scarcity of autoreactive 1191 human blood IgA + memory B cells

cryoSPARC: algorithms for rapid 1193 unsupervised cryo-EM structure determination

Non-uniform refinement: adaptive regularization improves 1195 single-particle cryo-EM reconstruction

SARS-CoV-2 B.1.1.7 (alpha) and B.1.351 (beta) 1198 variants induce pathogenic patterns in K18-hACE2 transgenic mice distinct from early strains

Convergent antibody responses to SARS-CoV-2 in 1202 convalescent individuals

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from 1205 disease in a small animal model

Post-exposure protection of SARS-CoV-2 lethal infected K18-hACE2 1208 transgenic mice by neutralizing human monoclonal antibody

Multivalency transforms SARS-CoV-2 antibodies into ultrapotent 1211 neutralizers

Antibody potency, effector function, and combinations 1214 in protection and therapy for SARS-CoV-2 infection in vivo

High genetic barrier to SARS-CoV-2 polyclonal 1217 neutralizing antibody escape

Adaptive immunity to SARS-CoV-2 and COVID-19

A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

Pathogenesis and transmission of SARS-CoV-2 in 1223 golden hamsters

SARS-CoV-2: Recent Variants and Clinical 1225 Efficacy of Antibody-Based Therapy

Distinct systemic and mucosal immune responses during acute 1228 SARS-CoV-2 infection

Maturation and persistence of the anti

CoV-2 memory B cell response

SARS-CoV-2 RBD antibodies that maximize breadth and 1234 resistance to escape

IgA dominates the early neutralizing antibody response to SARS-CoV-2

Increased in vitro neutralizing 1239 activity of SARS-CoV-2 IgA1 dimers compared to monomers and IgG

Efficient 1241 generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression 1242 vector cloning

Ultrapotent human antibodies protect against SARS-CoV-2 1245 challenge via multiple mechanisms

Discovery of ultrapotent broadly neutralizing 1248 antibodies from SARS-CoV-2 elite neutralizers

Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Ultrapotent antibodies against diverse and highly transmissible SARS-1253

CoV-2 variants. Science (80-. )

Enhanced SARS-CoV-2 neutralization by dimeric IgA

Naturally enhanced neutralizing breadth against 1259 SARS-CoV-2 one year after infection

Predominant Autoantibody Production by Early Human B Cell Precursors

Broad neutralization of SARS-related viruses by human 1264 monoclonal antibodies

LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-1267 2 variants

WHO Coronavirus (COVID-19) Dashboard

SARS-CoV-2 501Y.V2 escapes 1271 neutralization by South African COVID-19 donor plasma

MolProbity: More and better reference data for improved 1274 all-atom structure validation

Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector 1277 functions for optimal therapeutic protection

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Structural basis for the recognition of 1282 the SARS-CoV-2 by full-length human ACE2

Structural basis of a shared antibody response to SARS-CoV-2. Science

Structural and functional ramifications of antigenic drift in recent SARS-1288

CoV-2 variants. Science (80-. )

MotionCor2: 1290 anisotropic correction of beam-induced motion for improved cryo-electron microscopy

Evidence of escape of SARS-CoV-2 variant B.1.351 from 1294 natural and vaccine-induced sera

Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates 1297 with distinct epitopes on the RBD

New tools for automated high-resolution cryo-EM structure

Rapid isolation and profiling of a diverse panel of human 1302 monoclonal antibodies targeting the SARS-CoV-2 spike protein

Potently neutralizing and protective human antibodies against 1305 SARS-CoV-2

The average number of mutations 1362 is indicated below. Numbers of mutations were compared across groups of antibodies using 1363 unpaired student t-test with Welch's correction. (J) Circos plot (left) showing the clonal variants 1364 shared between distinct donors with the size of the links proportional to the number of clones 1365 sharing 75 % CDRH3 amino acid identity. Cladogram (right) showing the distribution of 1366 individual shared clones between donors. See also Table S1 and Figure S2. 1367 1368 Figure 3. Reactivity and antiviral activities of SARS-CoV-2 S-specific memory B-cell 1369 antibodies

CoV-2 antigens and trimeric spike proteins from other coronaviruses (α-coronaviruses

RBD, receptor binding 1372 domain; NTD, N-terminal domain; CD, connecting domain; FP, fusion peptide. Asterisks 1373 indicate the antibodies tested at a higher IgG concentration. (B) Schematic diagram showing 1374 the distribution of specificities of anti

CoV-2 spike as determined in (A) (ribbon representation of the PDB: 6VXX structure)

PseudoNeut.) assays against SARS-CoV-2. The bubble size corresponds to the 1379 blocking capacity of SARS-CoV-2 S-ACE2 interactions by the antibodies as measured by 1380 ELISA. Pie chart (right) show the distribution of non-active (white) vs neutralizing (shades of 1381 blue) antibodies according to neutralization % measured with the S-Fuse assay. (D) Dot plot 1382 showing the in vitro Fc-dependent effector activities of anti-S IgG antibodies (n=101)

ADCP, antibody-dependent cellular phagocytosis; CDC, complement-dependent cytotoxicity. 1386 (E) Matrix showing the correlation analyses between neutralization activities and Fc-1387 dependent effector functions measured for SARS-CoV-2 S-specific IgG antibodies

Radar plots comparing the in vitro neutralizing and Fc-dependent 1390 effector activities of anti-S IgG antibodies according to their targeted spike domains. Percent 1391 of antibodies per specificity group mediating a given antiviral activity as determined in (D) is 1392 shown. (G) Principal component analysis 2D-plot showing the antiviral-related variables 1393 discriminating anti-S mAbs color-coded by specificities. The two dimensions account for 77

S1 (purple) and RBD (pink) proteins. Calculated KD 1400 values are indicated at the bottom. (B) Competition ELISA graphs (left) comparing the IgG 1401 binding to SARS-CoV-2 tri-S (top) and RBD (bottom) of selected biotinylated anti-RBD 1402 antibodies in presence of Cv2.1169 as potential competitor. Means ± SD of duplicate values 1403 are shown. Heatmaps (right) showing the competition of selected anti-RBD nAbs for tri-S and 1404 RBD binding as measured in Figure S4D. Dark blue indicates stronger inhibition; lighter colors 1405 indicate weaker competition, and white, no competition. (C) Competition ELISA graphs 1406 showing the binding of biotinylated SARS-CoV-2 tri-S protein to the immobilized soluble ACE2 1407 ectodomain in presence of anti-RBD antibodies as competitors. Means ± SD of duplicate 1408 values are shown. (D) Graphs showing the neutralization curves of SARS-CoV-2 by selected 1409 anti-RBD IgG antibodies as determined with the pseudo-neutralization (top) and S-Fuse 1410 neutralization (bottom) assays. Error bars indicate the SD of assay triplicates. IC50 values are 1411 indicated in the top left-hand corner (in blue). (E) Heatmap comparing the binding of RBD-1412 specific IgG antibodies to the cell-expressed spike proteins of SARS-CoV-2 and selected viral 1413 variants as measured by flow cytometry. Geometric means of duplicate log10 ΔMFI values are 1414 shown in each cell. (F) Heatmaps comparing the binding (left) and RBD-ACE2 blocking 1415 capacity (right) of RBD-specific IgG antibodies for the RBD proteins of SARS-CoV-2 and 1416 selected viral variants as measured in Figures S4E-4H. Darker blue colors indicate high 1417 binding or competition while light colors show moderate binding or competition (white = no 1418 binding or competition). AUC values are shown in each cell. (G) Heatmaps comparing the IC50 1419 neutralizing values of the selected anti-RBD antibodies against SARS-CoV-2 and selected 1420 VOCs with the pseudo-neutralization (top) and S-Fuse neutralization (bottom) assays as 1421

5179 antibody as measured in Fig S6. (I) Radar plot comparing the binding of monomeric 1424

and to RBD 1425 from selected viral variants (in bold) as measured in Figure S4I. (J) Competition ELISA graphs 1426 (left) comparing the binding of biotinylated SARS-CoV-2 tri-S protein to the immobilized soluble 1427 ACE2 ectodomain in presence of Cv2.1169 IgG or IgA as a competitor

Error bars indicate the SD of triplicate values. n.dIgA, normalized 1433 values according to the number of binding sites. See also Tables S1 and S2, and Figures S3, 1434 S4, S5, S6 and S7. 1435 1436 Figure 5. Activity of Cv2.1169 against SARS-CoV-2 Omicron variants. (A) Heatmap (right) 1437 comparing the binding of RBD-specific IgG antibodies to the cell-expressed (CE) and soluble 1438 (tri-S) Omicron (ο) SARS-CoV-2 spike proteins as measured by flow cytometry (mean log10 1439 ΔMFI from duplicate values) and ELISA (mean AUC from duplicate values), respectively, as 1440 shown on the left for Cv2.1169. NT ctr, non-transfected cell control. The heatmap also presents 1441 the comparative antibody reactivity (AUC values) against β and ο RBD proteins. White 1442 indicates no binding. (B) Heatmap (bottom) comparing the RBD-ACE2 blocking capacity of 1443 neutralizing anti-RBD antibodies for the RBD proteins of SARS-CoV-2 and ο variant BA.1 as 1444 shown for Cv2.1169 (top)

Mean EC50 1455 from duplicate values are shown in each cell. (E) Graphs showing the neutralization curves of 1456 SARS-CoV-2 δ and ο BA.1 by potent anti-RBD IgG antibodies as determined with the S-Fuse 1457 neutralization assay. Error bars indicate the SD of duplicate values from 2 (Cv2.5179) or 5 1458 (Cv2.1169 and Cv2.3194) independent experiments. IC50 values are indicated (in blue for ο 1459 BA.1). ND, not determined. (F) Competition ELISA graphs showing the binding of biotinylated 1460 RBD proteins from SARS-CoV-2 o BA.1 and BA.2 variants to soluble ACE2 ectodomain in 1461 presence of Cv2.1169 and Cv2.3194 antibodies as competitors. Means ± SD of duplicate 1462 values are shown. (G) Same as in (F) but for Cv2.1169 and Cv2.3194 against BA.2. Error bars 1463 indicate the SD of duplicate values. (H) Graphs comparing the ELISA binding of monomeric 1464 and dimeric Cv2.1169 IgA antibodies to the RBD proteins of SARS-CoV-2 o BA.1 and BA.2 1465 variants. Means ± SD of duplicate values are shown

normalized values according to the number of binding sites. (J) Same as in (F) but for 1469

IgA monomers and J-chain dimers (dIgA) against BA.1 and BA.2. Error bars indicate 1470 the SD of duplicate values. Heatmap (right) presents the IC50 values calculated from the curves 1471 (left). n.dIgA

A) Crystal structure of the complex 1474 formed by the Receptor Binding Domain (RBD) and Cv2.1169. The RBD is represented in 1475 cartoon with a transparent surface, highlighting the Receptor Binding Motif (RBM, yellow) and 1476 residues that are mutated in the Variants of

1169 could not be built on the residual electron density and the variable domains are 1478 indicated in different shades of blue (IgH, dark blue; IgL, light blue). (B) Superposition of the 1479 RBD-Cv2.1169 and RBD-ACE2 (PDB: 6M0J) structures, showing the receptor on surface 1480 representation (light yellow) and its clashes with the antibody

Residues mutated in the VOCs are in red and the CDRH3 1483 disulfide bond is indicated with yellow sticks. (D) Details of the hydrophobic residues that 1484 anchor F486 at the interface between the light and heavy chains of Cv2.1169. (E) Identification 1485 of the Cv2.1169 epitope (blue) on the structure of a closed spike (PDB: 6VXX). The different 1486 protomers are identified with a subscript letter and colored in light grey (protomer A), dark grey 1487 (protomer B) and wheat (protomer C). (F) Cryo-EM map from the trimeric spike ectodomain in 1488 complex with Cv2.1169

Animals were infected intranasally (i.n.) with 10 4 1493 plaque forming units (PFU) of SARS-CoV-2 and received 6 h later an intraperitoneal (i.p.) 1494 injection of Cv2.1169 or isotypic control IgG antibody at ~ 10 mg/kg (0.25 mg) and ~ 20 mg/kg 1495 (0.5 mg). Graphs showing the evolution of initial body weight (% Δ weight, bottom left) and 1496 survival rate (bottom right) in animal groups

Animals were 1502 infected intranasally (i.n.) with 6x10 4 plaque forming units (PFU) of SARS-CoV-2 and received 1503 24 h later an intraperitoneal (i.p.) injection of PBS, Cv2.1169 or isotypic control IgG antibody 1504 at ~ 10 mg/kg (1 mg). Dot plots showing the lung weight / body weight ratio (LW/BW) x 100 1505 (left), infectivity (center) and RNA load (right) measured in animal groups at 5 dpi. Groups of 1506 hamsters were compared using two-tailed Mann-Whitney test

Same as in (A) but with K18-hACE2 mice infected with 10 4 PFU of the SARS-CoV-2 variant 1509 β (B.1.351), and either pre-treated 6h before infection with ~ 5 mg/kg (0.5 mg) of Cv2.1169 1510 IgA or treated 6h post-infection with ~ 5 mg/kg (0.5 mg) of Cv2

cohorts against SARS-CoV-2 tri-S and RBD proteins as measured in Figure S1B . Samples 1316were also tested against MERS tri-S to assay for cross-reactivity against another β-1317coronavirus. against SARS-CoV-2 S protein as measured by S-Flow (Y axis), tri-S ELISA (X axis) and tri-1329S-capture ELISA (bubble size). For each donor, the pie chart shows the proportion of SARS-1330CoV-2 S-specific antibodies from cloned antibodies (top; total number indicated in the pie chart 1331 center) and the number (n) of variants in each SARS-CoV-2 S-specific B-cell clonal family. 1332See also Table S1 and Figure S1 .